Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)

NCT01672853 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01672853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01672853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2013
Completion date
August 24, 2016
Enrollment
235 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis (psc)